These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9387111)

  • 1. Adverse effects of hyperhomocysteinemia and their management by folic acid.
    Perna AF; De Santo NG; Ingrosso D
    Miner Electrolyte Metab; 1997; 23(3-6):174-8. PubMed ID: 9387111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine and methionine metabolism in renal failure.
    van Guldener C; Stehouwer CD
    Semin Vasc Med; 2005 May; 5(2):201-8. PubMed ID: 16047272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperhomocysteinemia: an additional cardiovascular risk factor.
    Fanapour PC; Yug B; Kochar MS
    WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Homocysteine metabolism and risk of cardiovascular diseases: importance of the nutritional status on folic acid, vitamins B6 and B12].
    Alemán G; Tovar AR; Torres N
    Rev Invest Clin; 2001; 53(2):141-51. PubMed ID: 11421110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin.
    Perna AF; Castaldo P; Ingrosso D; De Santo NG
    J Nephrol; 1999; 12(4):230-40. PubMed ID: 10493566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
    Lovcić V; Kes P; Zeljko R; Kusec V
    Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine in uremia.
    Perna AF; Ingrosso D; Lombardi C; Cesare CM; Acantora F; Satta E; De Santo NG
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S123-6. PubMed ID: 12612968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia.
    Perna AF; Ingrosso D; De Santo NG; Galletti P; Brunone M; Zappia V
    J Am Soc Nephrol; 1997 Dec; 8(12):1899-905. PubMed ID: 9402092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrelations between plasma homocysteine and intracellular S-adenosylhomocysteine.
    Fu W; Dudman NP; Perry MA; Young K; Wang XL
    Biochem Biophys Res Commun; 2000 Apr; 271(1):47-53. PubMed ID: 10777679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Frequency of hyperhomocysteinemia in hemodialysis patients with folic acid supplementation].
    Kárpáti I; Balla J; Szóke G; Bereczky Z; Páll D; Ben T; Toma K; Katona E; Mohácsi A; Paragh G; Varga Z; Kakuk G; Muszbek L
    Orv Hetil; 2002 Jul; 143(27):1635-40. PubMed ID: 12180000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is homocysteine toxic in uremia?
    Perna AF; Luciano MG; Pulzella P; Satta E; Capasso R; Lombardi C; Ingrosso D; De Santo NG
    J Ren Nutr; 2008 Jan; 18(1):12-7. PubMed ID: 18089438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of homocysteine and its relationship with cardiovascular disease.
    Aguilar B; Rojas JC; Collados MT
    J Thromb Thrombolysis; 2004 Oct; 18(2):75-87. PubMed ID: 15789174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients].
    Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E
    Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of plasma homocysteine by folic acid in children with chronic renal failure.
    Kang HG; Lee BS; Hahn H; Lee JH; Ha IS; Cheong HI; Choi Y
    Pediatr Nephrol; 2002 Jul; 17(7):511-4. PubMed ID: 12172764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The methionine-homocysteine cycle and its effects on cognitive diseases.
    Miller AL
    Altern Med Rev; 2003 Feb; 8(1):7-19. PubMed ID: 12611557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma proteins containing damaged L-isoaspartyl residues are increased in uremia: implications for mechanism.
    Perna AF; Castaldo P; De Santo NG; di Carlo E; Cimmino A; Galletti P; Zappia V; Ingrosso D
    Kidney Int; 2001 Jun; 59(6):2299-308. PubMed ID: 11380834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients.
    Alvares Delfino VD; de Andrade Vianna AC; Mocelin AJ; Barbosa DS; Mise RA; Matsuo T
    Nutrition; 2007 Mar; 23(3):242-7. PubMed ID: 17321110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure.
    Bernasconi AR; Liste A; Del Pino N; Rosa Diez GJ; Heguilén RM
    Nephrology (Carlton); 2006 Apr; 11(2):137-41. PubMed ID: 16669976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.